	US 12,270,050 B2
	Human T cell derived from T cell-derived induced pluripotent stem cell and methods of making and using
Bruce R. Blazar, Golden Valley, MN (US); Dharmeshkumar Patel, Falcon Heights, MN (US); Beau R. Webber, Coon Rapids, MN (US); and Jakub Tolar, Minneapolis, MN (US)
Assigned to REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Appl. No. 16/060,651
Filed by Regents of the University of Minnesota, Minneapolis, MN (US)
PCT Filed Dec. 8, 2016, PCT No. PCT/US2016/065524 § 371(c)(1), (2) Date Jun. 8, 2018, PCT Pub. No. WO2017/100403, PCT Pub. Date Jun. 15, 2017.
Claims priority of provisional application 62/264,455, filed on Dec. 8, 2015.
Prior Publication US 2018/0362927 A1, Dec. 20, 2018
Int. Cl. A61K 35/545 (2015.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C12N 5/074 (2010.01); C12N 5/0783 (2010.01)

CPC C12N 5/0636 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); C12N 5/0696 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/26 (2013.01); C12N 2501/415 (2013.01); C12N 2501/42 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2506/11 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01); C12N 2533/90 (2013.01)]

18 Claims

1. A method comprising:

isolating at least one stem memory T cell (Tsm);

expanding the Tsm in vitro;

reprogramming at least a portion of the expanded Tsms into iPSCs; and

differentiating at least a portion of the iPSCs into T cells, wherein differentiating comprises forming embryoid bodies (EBs) from the iPSCs and culturing the iPSCs in the presence of a Wnt pathway activator and a TGFβ signaling inhibitor, wherein the differentiated T cells comprise a Tsm.